TMEM92

Summary

TMEM92 (transmembrane protein 92, HGNC:26579) is a protein-coding gene on chromosome 17q21.33, encoding Transmembrane protein 92 (Q6UXU6).

Located in nucleoplasm.

Source: NCBI Gene 162461 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nervous system disorder (Limited, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 34 total — 1 likely-pathogenic
• MANE Select transcript: NM_153229

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26579
Approved symbol	TMEM92
Name	transmembrane protein 92
Location	17q21.33
Locus type	gene with protein product
Status	Approved
Aliases	FLJ33318
Ensembl gene	ENSG00000167105
Ensembl biotype	protein_coding
OMIM	619604
Entrez	162461

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000300433, ENST00000507382, ENST00000511882, ENST00000863234, ENST00000863235, ENST00000918452, ENST00000918453

RefSeq mRNA: 2 — MANE Select: NM_153229 NM_001168215, NM_153229

CCDS: CCDS11562

Canonical transcript exons

ENST00000507382 — 5 exons

Exon	Start	End
ENSE00001109672	50278801	50278996
ENSE00001223376	50279195	50281485
ENSE00002081882	50274466	50274570
ENSE00003625300	50278556	50278630
ENSE00003636125	50277715	50277740

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 95.42.

FANTOM5 (CAGE): breadth broad, TPM avg 4.1142 / max 264.5018, expressed in 515 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161649	4.0260	512
161648	0.0477	11
161650	0.0290	11
161651	0.0115	5

Top tissues by expression

229 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	95.42	silver quality
ileal mucosa	UBERON:0000331	91.29	gold quality
duodenum	UBERON:0002114	85.65	gold quality
jejunal mucosa	UBERON:0000399	83.30	gold quality
tibialis anterior	UBERON:0001385	82.39	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.93	gold quality
upper arm skin	UBERON:0004263	78.71	gold quality
kidney epithelium	UBERON:0004819	78.71	gold quality
deltoid	UBERON:0001476	78.56	gold quality
cardia of stomach	UBERON:0001162	78.25	gold quality
body of stomach	UBERON:0001161	78.02	gold quality
cardiac muscle of right atrium	UBERON:0003379	77.67	gold quality
jejunum	UBERON:0002115	77.07	gold quality
small intestine	UBERON:0002108	76.99	gold quality
left ventricle myocardium	UBERON:0006566	76.97	gold quality
small intestine Peyer’s patch	UBERON:0003454	76.25	gold quality
sperm	CL:0000019	75.92	gold quality
stomach	UBERON:0000945	75.83	gold quality
nasal cavity epithelium	UBERON:0005384	75.81	gold quality
vena cava	UBERON:0004087	75.31	gold quality
oocyte	CL:0000023	75.28	gold quality
gall bladder	UBERON:0002110	75.23	gold quality
quadriceps femoris	UBERON:0001377	74.56	gold quality
vastus lateralis	UBERON:0001379	73.32	gold quality
mucosa of sigmoid colon	UBERON:0004993	73.12	silver quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	72.34	gold quality
myocardium	UBERON:0002349	72.19	gold quality
substantia nigra pars compacta	UBERON:0001965	71.54	gold quality
colonic mucosa	UBERON:0000317	71.07	gold quality
pylorus	UBERON:0001166	70.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.25

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

83 targeting TMEM92, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-345-3P	99.89	70.23	1421

Literature-anchored findings (GeneRIF, showing 1)

• Transmembrane protein 92 performs a tumor-promoting function in breast carcinoma by contributing to the cell growth, invasion, migration and epithelial-mesenchymal transition. (PMID:32835947)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tmem92	ENSMUSG00000075610
rattus_norvegicus	LOC100364194	ENSRNOG00000062464
rattus_norvegicus	LOC103693451	ENSRNOG00000070607
rattus_norvegicus		ENSRNOG00000070925
rattus_norvegicus		ENSRNOG00000074786

Protein

Protein identifiers

Transmembrane protein 92 — Q6UXU6 (reviewed: Q6UXU6)

All UniProt accessions (1): Q6UXU6

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

RefSeq proteins (2): NP_001161687, NP_694961* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021684	WBP1-like	Family

Pfam: PF11669

UniProt features (9 total): sequence variant 3, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UXU6-F1	67.18	0.07

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 34 (showing top): NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, NUYTTEN_NIPP1_TARGETS_DN, MARTENS_TRETINOIN_RESPONSE_UP, FORTSCHEGGER_PHF8_TARGETS_DN, NOTCH_DN.V1_DN, GSE10094_LCMV_VS_LISTERIA_IND_EFF_CD4_TCELL_DN, MIR3685, MIR4283, MIR5006_5P, MIR4755_3P, MIR6767_3P, GSE13485_DAY1_VS_DAY3_YF17D_VACCINE_PBMC_UP, GSE16522_ANTI_CD3CD28_STIM_VS_UNSTIM_NAIVE_CD8_TCELL_DN, DESCARTES_FETAL_CEREBELLUM_VASCULAR_ENDOTHELIAL_CELLS, DESCARTES_FETAL_CEREBRUM_VASCULAR_ENDOTHELIAL_CELLS

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): nucleoplasm (GO:0005654), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
binding	1
nuclear lumen	1

Protein interactions and networks

STRING

390 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM92	ZSCAN4	Q8NAM6	586
TMEM92	CLVS1	Q8IUQ0	522
TMEM92	N4BP2L1	Q5TBK1	515
TMEM92	ZNF618	Q5T7W0	491
TMEM92	KRTAP9-7	A8MTY7	478
TMEM92	PRAMEF6	Q5VXH4	471
TMEM92	TRIM28	Q13263	443
TMEM92	TMEM54	Q969K7	433
TMEM92	PRAMEF25	A6NGN4	413
TMEM92	USP17L1	Q7RTZ2	380
TMEM92	OR1E2	P47887	379
TMEM92	KRTAP9-8	Q9BYQ0	379
TMEM92	OR1D5	P58170	368
TMEM92	ZNF589	Q86UQ0	358
TMEM92	KRTAP9-1	A8MXZ3	350
TMEM92	OR3A2	P47893	350

IntAct

14 interactions, top by confidence:

A	B	Type	Score
RTP2	TMEM92	psi-mi:“MI:0915”(physical association)	0.560
TMEM92	DERL3	psi-mi:“MI:0915”(physical association)	0.560
YAP1	TMEM92	psi-mi:“MI:0407”(direct interaction)	0.440
PARD6B	PARD3	psi-mi:“MI:0914”(association)	0.350
Sgo2a	GPA33	psi-mi:“MI:0914”(association)	0.350
Nelfa	NELFE	psi-mi:“MI:0914”(association)	0.350
MRPL9	MRPL43	psi-mi:“MI:0914”(association)	0.350
TMEM92	NEDD4	psi-mi:“MI:0914”(association)	0.350
RTP2	TMEM92	psi-mi:“MI:0915”(physical association)	0.000
DERL3	TMEM92	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (34): WWOX (Affinity Capture-MS), NEDD4 (Affinity Capture-MS), ITCH (Affinity Capture-MS), NEDD4L (Affinity Capture-MS), POMT2 (Affinity Capture-MS), POMT1 (Affinity Capture-MS), NDFIP1 (Affinity Capture-MS), HBB (Affinity Capture-MS), CUEDC1 (Affinity Capture-MS), CTDNEP1 (Affinity Capture-MS), TMEM92 (Affinity Capture-MS), TMEM92 (Affinity Capture-MS), TMEM92 (Affinity Capture-MS), TMEM92 (Affinity Capture-MS), WWOX (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GSZ0, A0A1B0GU29, A2A9G7, A2AR95, A2RV66, A4IHY6, A6NKW6, A6QQ93, A7Z070, B7ZWI3, D5LX53, F5HHZ3, O14668, O14669, O88472, P16815, P86045, P98153, P98154, Q02223, Q0VBF2, Q16655, Q4W815, Q56A20, Q5R8E0, Q5RCB6, Q5RCS3, Q5RF75, Q68FU0, Q69559, Q6AXS2, Q6F6K2, Q6UWV7, Q6UWW9, Q6UXU6, Q6XQ84, Q7SXB3, Q7TMJ8, Q86YD5, Q8BGN6

Diamond homologs: B7ZWI3, Q6UXU6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	28
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
183355	NM_153229.3(TMEM92):c.95+3A>G	Likely pathogenic

SpliceAI

735 predictions. Top by Δscore:

Variant	Effect	Δscore
17:50277741:G:GG	donor_gain	1.0000
17:50279190:TGCA:T	acceptor_loss	1.0000
17:50279191:GCA:G	acceptor_loss	1.0000
17:50279192:CA:C	acceptor_loss	1.0000
17:50279193:A:AG	acceptor_gain	1.0000
17:50279193:AGGT:A	acceptor_gain	1.0000
17:50279194:G:GG	acceptor_gain	1.0000
17:50279194:GGT:G	acceptor_gain	1.0000
17:50279194:GGTG:G	acceptor_gain	1.0000
17:50278540:T:TA	acceptor_gain	0.9900
17:50278542:T:TA	acceptor_gain	0.9900
17:50278549:T:TA	acceptor_gain	0.9900
17:50278554:A:AG	acceptor_gain	0.9900
17:50278555:G:GA	acceptor_gain	0.9900
17:50278555:GT:G	acceptor_gain	0.9900
17:50278555:GTGC:G	acceptor_gain	0.9900
17:50279193:AG:A	acceptor_gain	0.9900
17:50279194:GG:G	acceptor_gain	0.9900
17:50277711:ACAG:A	acceptor_loss	0.9800
17:50277712:CAGAT:C	acceptor_loss	0.9800
17:50277713:A:AG	acceptor_gain	0.9800
17:50277713:A:T	acceptor_loss	0.9800
17:50277714:G:GC	acceptor_loss	0.9800
17:50277714:G:GG	acceptor_gain	0.9800
17:50277739:CTGT:C	donor_loss	0.9800
17:50277740:TG:T	donor_loss	0.9800
17:50277741:GTAA:G	donor_loss	0.9800
17:50277742:T:TC	donor_loss	0.9800
17:50277743:AA:A	donor_loss	0.9800
17:50277753:GCCA:G	donor_gain	0.9800

AlphaMissense

1030 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:50278841:T:C	C71R	0.916
17:50279303:T:C	F159L	0.915
17:50279305:C:A	F159L	0.915
17:50279305:C:G	F159L	0.915
17:50278988:T:G	Y120D	0.899
17:50278988:T:C	Y120H	0.895
17:50279206:G:C	K126N	0.890
17:50279206:G:T	K126N	0.890
17:50278578:T:A	C40S	0.885
17:50278579:G:C	C40S	0.885
17:50278593:T:A	C45S	0.885
17:50278594:G:C	C45S	0.885
17:50278560:T:C	C34R	0.876
17:50278578:T:C	C40R	0.874
17:50278593:T:C	C45R	0.874
17:50278988:T:A	Y120N	0.865
17:50279196:T:C	V123A	0.861
17:50278560:T:A	C34S	0.855
17:50278561:G:C	C34S	0.855
17:50278989:A:G	Y120C	0.852
17:50278581:T:A	C41S	0.847
17:50278582:G:C	C41S	0.847
17:50279246:T:C	Y140H	0.841
17:50279246:T:G	Y140D	0.837
17:50278596:T:A	C46S	0.831
17:50278597:G:C	C46S	0.831
17:50278989:A:C	Y120S	0.831
17:50279249:A:C	S141R	0.823
17:50279251:C:A	S141R	0.823
17:50279251:C:G	S141R	0.823

dbSNP variants (sampled 300 via entrez): RS1000003484 (17:50278210 C>G,T), RS1000244385 (17:50276281 C>T), RS1000546016 (17:50278426 C>T), RS1000632762 (17:50270531 G>C), RS1000830061 (17:50271013 G>A,T), RS1001177087 (17:50277904 C>A,T), RS1001227421 (17:50271770 A>G), RS1001609522 (17:50275392 G>A,T), RS1001618239 (17:50272190 T>A), RS1001713457 (17:50278176 C>T), RS1001779268 (17:50269979 C>T), RS1001848321 (17:50274466 C>G,T), RS1001855821 (17:50277593 A>G), RS1001914598 (17:50275588 C>A,T), RS1002343212 (17:50274231 G>A)

Disease associations

OMIM: gene MIM:619604 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
nervous system disorder	Limited	Autosomal recessive

Mondo (2): hydrocephalus (MONDO:0001150), nervous system disorder (MONDO:0005071)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006288_291	Heel bone mineral density	4.000000e-18
GCST006288_360	Heel bone mineral density	7.000000e-08
GCST006288_58	Heel bone mineral density	1.000000e-09
GCST006979_502	Heel bone mineral density	9.000000e-31

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D006849	Hydrocephalus	C10.228.140.602
D009422	Nervous System Diseases	C10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	5
Benzo(a)pyrene	increases expression, increases mutagenesis	2
Estradiol	decreases expression, affects cotreatment, increases expression	2
Smoke	decreases expression, increases expression	2
sotorasib	affects cotreatment, decreases expression	1
propionaldehyde	increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	decreases methylation	1
entinostat	increases expression	1
abrine	decreases expression	1
licochalcone B	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Bortezomib	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Methapyrilene	decreases methylation	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	increases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

423 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00560157	PHASE4	COMPLETED	Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients
NCT01319643	PHASE4	UNKNOWN	Normal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU)
NCT01662414	PHASE4	COMPLETED	Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson’s Disease
NCT04289142	PHASE4	RECRUITING	Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT04386525	PHASE4	UNKNOWN	Omega 3 and Ischemic Stroke; Fish Oil as an Option
NCT04871464	PHASE4	UNKNOWN	Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson’s Disease
NCT04970667	PHASE4	COMPLETED	Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder
NCT05068349	PHASE4	UNKNOWN	For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT06382467	PHASE4	UNKNOWN	Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM
NCT06406127	PHASE4	RECRUITING	Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients
NCT01323764	PHASE4	COMPLETED	ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients
NCT01685450	PHASE4	UNKNOWN	NIMIP: Non Invasive Measurement of the Intracranial Pressure
NCT03513757	PHASE4	COMPLETED	Dexmedetomidine and Propofol for Pediatric MRI Sedation
NCT07547826	PHASE4	NOT_YET_RECRUITING	Efficacy and Cost-Effectiveness of Topical Vancomycin Powder in Preventing Pediatric Ventriculoperitoneal Shunt Infections Across Different Etiologies
NCT00240695	PHASE3	COMPLETED	A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
NCT01313299	PHASE3	COMPLETED	Dysport® Adult Upper Limb Spasticity
NCT01313312	PHASE3	COMPLETED	Dysport® Adult Upper Limb Spasticity Extension Study
NCT01425983	PHASE3	COMPLETED	Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01)
NCT01589289	PHASE3	COMPLETED	Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
NCT01826487	PHASE3	COMPLETED	Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
NCT01862640	PHASE3	COMPLETED	A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer’s Agitation
NCT01922258	PHASE3	COMPLETED	Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type
NCT02090959	PHASE3	TERMINATED	An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
NCT02284126	PHASE3	COMPLETED	Topical Vancomycin for Neurosurgery Wound Prophylaxis
NCT02436096	PHASE3	COMPLETED	A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
NCT02770807	PHASE3	COMPLETED	Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
NCT02829814	PHASE3	TERMINATED	Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
NCT03179631	PHASE3	COMPLETED	Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
NCT03336450	PHASE3	COMPLETED	Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting
NCT03336645	PHASE3	COMPLETED	Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
NCT04639310	PHASE3	TERMINATED	XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
NCT04912856	PHASE3	TERMINATED	An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
NCT05126758	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05508789	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5)
NCT05738486	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 6)
NCT05834855	PHASE3	RECRUITING	Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
NCT06672237	PHASE3	RECRUITING	A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT06819592	PHASE3	RECRUITING	PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury